Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide

2003 ◽  
Vol 18 (7) ◽  
pp. 653-655 ◽  
Author(s):  
Georg Adler ◽  
Martin Teufel ◽  
Lutz M. Drach
Keyword(s):  
Treatment Response ◽  
Frontotemporal Dementia ◽  
Pharmacological Treatment ◽  
Mao A ◽  
Dementia Treatment

Expression Biomarkers of Pharmacological Treatment Outcomes in Women with Unipolar and Bipolar Depression

2021 ◽  
Author(s):  
Monika Dmitrzak-Weglarz ◽  
Aleksandra Szczepankiewicz ◽  
Janusz Rybakowski ◽  
Paweł Kapelski ◽  
Karolina Bilska ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profiling ◽  
Treatment Outcomes ◽  
Treatment Response ◽  
Pharmacological Treatment ◽  
Expression Profiling ◽  
Mononuclear Cells ◽  
Rating Scale ◽  
Bipolar Depression ◽  
Hospital Setting

Abstract Introduction This study aimed to find the expression biomarkers of pharmacological treatment response in a naturalistic hospital setting. Through gene expression profiling, we were able to find differentially-expressed genes (DEGs) in unipolar (UD) and bipolar (BD) depressed women. Methods We performed gene expression profiling in hospitalized women with unipolar (n=24) and bipolar depression (n=32) who achieved clinical improvement after pharmacological treatment (without any restriction). To identify DEGs in peripheral blood mononuclear cells (PBMCs), we used the SurePrint G3 Microarray and GeneSpring software. Results After pharmacological treatment, UD and BD varied in the number of regulated genes and ontological pathways. Also, the pathways of neurogenesis and synaptic transmission were significantly up-regulated. Our research focused on DEGs with a minimum fold change (FC) of more than 2. For both types of depression, 2 up-regulated genes, OPRM1 and CELF4 (p=0.013), were significantly associated with treatment response (defined as a 50% reduction on the Hamilton Depression Rating Scale [HDRS]). We also uncovered the SHANK3 (p=0.001) gene that is unique for UD and found that the RASGRF1 (p=0.010) gene may be a potential specific biomarker of treatment response for BD. Conclusion Based on transcriptomic profiling, we identified potential expression biomarkers of treatment outcomes for UD and BD. We also proved that the Ras-GEF pathway associated with long-term memory, female stress response, and treatment response modulation in animal studies impacts treatment efficacy in patients with BD. Further studies focused on the outlined genes may help provide predictive markers of treatment outcomes in UD and BD.

scholarly journals End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer’s Disease

2020 ◽  
Vol 77 (3) ◽  
pp. 1169-1180
Author(s):  
Marie-Paule E. van Engelen ◽  
Flora T. Gossink ◽  
Lieke S. de Vijlder ◽  
Jan R.A. Meursing ◽  
Philip Scheltens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Frontotemporal Dementia ◽  
Cause Of Death ◽  
Clinical Features ◽  
Pharmacological Treatment ◽  
Family Members ◽  
Behavioral Variant Frontotemporal Dementia ◽  
Young Onset ◽  
End Stage

Background: Limited literature exists regarding the clinical features of end stage behavioral variant frontotemporal dementia (bvFTD). This data is indispensable to inform and prepare family members as well as professional caregivers for the expected disease course and to anticipate with drug-based and non-pharmacological treatment strategies. Objective: The aim of the present study was to describe end stage bvFTD in a broad explorative manner and to subsequently evaluate similarities and dissimilarities with the end stage of the most prevalent form of young-onset dementia, Alzheimer’s disease (yoAD). Methods: We analyzed medical files on patients, using a mixed model of qualitative and quantitative approaches. Included were previously deceased patients with probable bvFTD and probable yoAD. End stage was defined as the last 6 months prior to death. Primary outcome measures comprised somatic, neurological, and psychiatric symptoms and the secondary outcome measure was cause of death. Results: Out of 89 patients, a total of 30 patients were included (bvFTD; n = 12, yoAD; n = 18). Overall, the end stages of bvFTD and yoAD were characterized by a broad spectrum of clinical symptoms including severe autonomic dysfunction and an increased muscle tone. Patients with bvFTD displayed more mutism compared with yoAD while compulsiveness was only present in bvFTD. Conclusion: Our study describes the full clinical spectrum of end stage bvFTD and yoAD. In this study, symptoms extend far beyond the initial behavioral and cognitive features. By taking both somatic, psychiatric, and neurological features into account, family members and professional caregivers may anticipate (non) pharmacological treatment.

P2-435: The chessboard square of frontotemporal dementia treatment: Results from a prospective multicenter study

2008 ◽  
Vol 4 ◽  
pp. T501-T501
Author(s):  
◽  
Bernd Ibach ◽  
Hans Gutzmann ◽  
Stefan Poljanski ◽  
Winfried Barta ◽  
...  
Keyword(s):  
Frontotemporal Dementia ◽  
Multicenter Study ◽  
Treatment Results ◽  
Prospective Multicenter Study ◽  
Dementia Treatment
Sign in / Sign up

Export Citation Format

Share Document